The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
Open accessAbstract
A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal models of infections with other coronaviruses and for previous whole-cell inactivated vaccines developed for respiratory syncytial virus and measles virus, VAERD has usually been associated with the development of T helper 2 cell (TH2 cell)-biased CD4+ T cell responses, with significantly increased levels of interleukin-4 (IL-4), IL-5 and/or IL-13 (refs12,126,165–174).”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Self-citationKIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
Self-citationImmunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
Self-citationLethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010
Self-citationComparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
Self-citationA DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688
Self-citationCorrelates of adjuvanticity: A review on adjuvants in licensed vaccines
Giudice, G. D., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 631
Self-citationTseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 562
Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H.-Y., Mitzner, W., et al. (2008) · Nature Medicine · doi:10.1038/nm.1894 · Cited by 498
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477
Self-citationA Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice
Roberts, A., Deming, D., Paddock, C. D., Cheng, A., Yount, B. L., Vogel, L., Herman, B. D., Sheahan, T., Heise, M. T., Genrich, G. L., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030005 · Cited by 447
Self-citationA Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner, M., Regele, H. M., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020781 · Cited by 402
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Giudice, G. D., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 357
Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C.-Y., Morse, H. C., & Murphy, B. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5321-5325.1994 · Cited by 347
Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344
Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
Smits, S. L., de Lang, A., van den Brand, J. M. A., Leijten, L. M. E., van IJcken, W. F. J., Eijkemans, M. J. C., van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000756 · Cited by 332
Jaume, M., Yip, M., Cheung, C. Y., Leung, N., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R. M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 312
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 299
Self-citationSevere Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters
Roberts, A., Vogel, L., Guarner, J., Hayes, N., Murphy, B. R., Zaki, S. R., & Subbarao, K. (2004) · Journal of Virology · doi:10.1128/jvi.79.1.503-511.2005 · Cited by 283
Self-citationAge‐related rhesus macaque models of COVID‐19
Yu, P., Qi, F., Xu, Y., Li, F., Liu, P., Liu, J., Bao, L., Deng, W., Gao, H., Xiang, Z., et al. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12108 · Cited by 275
Self-citationDeming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 273
Self-citationConnors, M., Kulkarni, A. B., Firestone, C.-Y., Holmes, K. L., Morse, H. C., Sotnikov, A. V., & Murphy, B. R. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.7444-7451.1992 · Cited by 271
Agrawal, A. S., Tao, X., Algaissi, A. A., Garron, T. M., Narayanan, K., Peng, B., Couch, R. B., & Tseng, C.-T. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1177688 · Cited by 267
Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses
Zhao, J., Alshukairi, A. N., Baharoon, S. A., Ahmed, W., Bokhari, A. A., Nehdi, A., Layqah, L. A., Alghamdi, M., Algethamy, M., Dada, A. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5393 · Cited by 262
Self-citationAntibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
Yip, M., Leung, N., Cheung, C. Y., Li, P. H., Lee, H. H. Y., Daëron, M., Peiris, M. J. S., Bruzzone, R., & Jaume, M. (2014) · Virology Journal · doi:10.1186/1743-422x-11-82 · Cited by 249
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 248
Sun, P., Schwenk, R., White, K., Stoute, J. A., Cohen, J., Ballou, W. R., Voss, G., Kester, K. E., Heppner, D. G., & Krzych, U. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6961 · Cited by 232
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
Cockrell, A. S., Yount, B. L., Scobey, T., Jensen, K., Douglas, M. G., Beall, A. E., Tang, X.-C., Marasco, W. A., Heise, M. T., & Baric, R. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.226 · Cited by 209
Self-citationMcAuliffe, J. M., Vogel, L., Roberts, A., Fahle, G. A., Fischer, S. H., Shieh, W., Butler, E. L., Zaki, S. R., Claire, M. S., Murphy, B. R., et al. (2004) · Virology · doi:10.1016/j.virol.2004.09.030 · Cited by 203
Self-citationRoberts, A., Paddock, C. D., Vogel, L., Butler, E. L., Zaki, S. R., & Subbarao, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5833-5838.2005 · Cited by 196
Self-citationMouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
Li, K., Wohlford-Lenane, C., Channappanavar, R., Park, J.-E., Earnest, J. T., Bair, T., Bates, A. M., Brogden, K. A., Flaherty, H. A., Gallagher, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619109114 · Cited by 184
Self-citationKim, T. W., Lee, J. H., Hung, C., Peng, S., Roden, R. B. S., Wang, M., Viscidi, R. P., Tsai, Y.-C., He, L., Chen, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4638-4645.2004 · Cited by 172
Moris, P., der Most, R. G. V., Leroux‐Roels, I., Clément, F., Dramé, M., Hanon, E., Leroux-Roels, G. G., & Mechelen, M. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9490-6 · Cited by 159
Burny, W., Callegaro, A., Bechtold, V., Clément, F., Delhaye, S., Fissette, L. A., Janssens, M., Leroux-Roels, G. G., Marchant, A., van den Berg, R. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00943 · Cited by 151
Self-citationFrieman, M. B., Yount, B. L., Agnihothram, S., Page, C., Donaldson, E., Roberts, A., Vogel, L., Woodruff, B., Scorpio, D. G., Subbarao, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05957-11 · Cited by 141
Self-citationViral-Induced Enhanced Disease Illness
Smatti, M. K., Thani, A. A. A., & Yassine, H. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02991 · Cited by 128
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
Enjuanes, L., DeDiego, M. L., Álvarez, E. A., Deming, D., Sheahan, T., & Baric, R. S. (2007) · Virus Research · doi:10.1016/j.virusres.2007.01.021 · Cited by 119
Self-citationLeroux-Roels, G. G., Marchant, A., Lévy, J., Damme, P. V., Schwarz, T. F., Horsmans, Y., Jilg, W., Kremsner, P. G., Haelterman, E., Clément, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.007 · Cited by 113
Self-citationTowards an evidence based approach for the development of adjuvanted vaccines
O’Hagan, D. T., Friedland, L. R., Hanon, E., & Didierlaurent, A. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.010 · Cited by 107
Self-citationThe SARS-CoV ferret model in an infection–challenge study
Chu, Y., Ali, G. D., Jia, F., Li, Q., Kelvin, D. J., Couch, R. C., Harrod, K. S., Hutt, J. A., Cameron, C., Weiss, S. R., et al. (2008) · Virology · doi:10.1016/j.virol.2007.12.032 · Cited by 107
Francica, J. R., Zak, D. E., Linde, C., Siena, E., Johnson, C. D., Juraska, M., Yates, N. L., Gunn, B. M., Gregorio, E. D., Flynn, B. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011411 · Cited by 91
Khurana, S., Coyle, E. M., Manischewitz, J. F., King, L. R., Gao, J., Germain, R. N., Schwartzberg, P. L., Tsang, J. S., Golding, H., Biancotto, A., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0076-2 · Cited by 75
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
Qin, E.-D., Shi, H., Tang, L., Wang, C., Chang, G., Ding, Z., Zhao, K., Wang, J., Chen, Z., Yu, M., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.038 · Cited by 75
Johnson, R. F., Bağcı, U., Keith, L. A., Tang, X., Mollura, D. J., Zeitlin, L., Qin, J., Huzella, L., Bartos, C., Bohorova, N., et al. (2016) · Virology · doi:10.1016/j.virol.2016.01.004 · Cited by 75
Self-citationHashem, A. M., Algaissi, A. A., Agrawal, A. S., Alamri, S. S., Alhabbab, R. Y., Sohrab, S. S., Almasoud, A. S., Alharbi, N. K., Peng, B., Russell, M. S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz137 · Cited by 72
Roberts, A., Lamirande, E. W., Vogel, L., Baras, B., Goossens, G., Knott, I., Chen, J., Ward, J. M., Vassilev, V. B., & Subbarao, K. (2010) · Viral Immunology · doi:10.1089/vim.2010.0028 · Cited by 70
Self-citationSelective induction of antibody effector functional responses using MF59-adjuvanted vaccination
Boudreau, C. M., Yu, W., Suscovich, T. J., Talbot, H. K., Edwards, K. M., & Alter, G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129520 · Cited by 70
Sheahan, T. P., Whitmore, A. C., Long, K. M., Ferris, M. T., Rockx, B., Funkhouser, W. K., Donaldson, E., Gralinski, L. E., Collier, M., Heise, M. T., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01805-10 · Cited by 69
Self-citationGalson, J. D., Trück, J., Kelly, D. F., & der Most, R. G. V. (2016) · Scientific Reports · doi:10.1038/srep37229 · Cited by 61
Douglas, M. G., Kocher, J., Scobey, T., Baric, R. S., & Cockrell, A. S. (2017) · Virology · doi:10.1016/j.virol.2017.12.006 · Cited by 56
Self-citationSystems analysis of human vaccine adjuvants
Harandi, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.08.001 · Cited by 54
Johnson, R. F., Via, L. E., Kumar, M. R., Cornish, J. P., Yellayi, S., Huzella, L., Postnikova, E. N., Oberlander, N., Bartos, C., Ork, B. L., et al. (2015) · Virology · doi:10.1016/j.virol.2015.07.013 · Cited by 48
Couch, R. B., Bayas, J. M., Caso, C., Mbawuike, I. N., López, C. N., Claeys, C., Idrissi, M. E., Hervé, C., Laupèze, B., Oostvogels, L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-425 · Cited by 42
Roberts, A., Wood, J., Subbarao, K., Ferguson, M., Wood, D., & Cherian, T. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.07.009 · Cited by 15
Self-citationWang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00148 · Cited by 10
Self-citation
Cited by
Sorted by citations
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationAging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694
Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30773-8 · Cited by 633
Self-citationImmunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Metadata
- Authors
- Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., Molrine, D. C., Perlman, S., Picard-Fraser, P. A., Pollard, A. J., Qin, C., Subbarao, K., & Cramer, J. P.
- Affiliations
- University of Geneva (CH)
- Coalition for Epidemic Preparedness Innovations (NO)
- University of North Carolina at Chapel Hill (US)
- The Task Force for Global Health (US)
- National Institutes of Health (US)
- University of Iowa (US)
- University of Oxford (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peter Doherty Institute (AU)
- Coalition for Epidemic Preparedness Innovations (US)
- Corresponding author
- Dekker, Cornelia L.
- ORCID
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 38
- Issue
- 31
- Pages
- 4783-4791
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC7247514
- OpenAlex
- W3031777395
- Cited by
- 119
- References
- 59
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 24 · 2021: 40 · 2020: 36
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Vaccine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion, cc-by-nc-nd)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- Coalition for Epidemic Preparedness Innovations
- National Institute of Allergy and Infectious Diseases (P01AI060699, R01AI129269)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2, disease enhancement, vaccine safety, vaccine design, animal models, RSV vaccine, vaccine immunology
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Antibodies, Viral, Clinical Trials as Topic, Disease Models, Animal, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Risk Assessment, Severe Acute Respiratory Syndrome, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
